Adaptive Biotechnologies Corporation (1HM.F)
Frankfurt · EUR · Healthcare · Diagnostics & Research
€23.28 (+3.33%) as of
Key statistics
- Market cap
- 3.72B
- Forward P/E
- -14.37
- EPS (TTM)
- -0.37
- Dividend yield
- 0.00%
- 52-week range
- 10.65 – 26.25
- Beta
- 2.10
- Revenue (TTM)
- 308.08M
- Profit margin
- -20.73%
- Volume
- 150.00
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Seattle, WA, United States
- Employees
- 624
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.